New pill tested as potential lifeline for Tough-to-Treat cancers
NCT ID NCT06264921
Summary
This early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specific cancers, including ovarian cancer with a certain genetic feature.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Cancer Institute
Celebration, Florida, 34747, United States
-
Augusta University Georgia Cancer Center
Augusta, Georgia, 30909, United States
-
Norton Cancer Institute - Broadway
Louisville, Kentucky, 40202, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Texas Oncology-Austin Midtown NEXT Oncology
Austin, Texas, 78758, United States
-
The Gabrail Pharmacology Phase 1 Research Center
Canton, Ohio, 44718, United States
-
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.